Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison

INTRODUCTION: Apalutamide and darolutamide are next-generation androgen receptor inhibitors that have demonstrated superior efficacy compared to placebo in men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT). In the absence of head-to-he...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdhury, Simon, Oudard, Stephane, Uemura, Hiroji, Joniau, Steven, Dearden, Lindsay, Capone, Camille, Van Sanden, Suzy, Diels, Joris, Hadaschik, Boris A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799579/
https://www.ncbi.nlm.nih.gov/pubmed/34797506
http://dx.doi.org/10.1007/s12325-021-01885-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799579/
https://www.ncbi.nlm.nih.gov/pubmed/34797506
http://dx.doi.org/10.1007/s12325-021-01885-6

Ejemplares similares